A recent study from Brunel University of London has uncovered potential new applications for a protein commonly used in cancer diagnostics. This protein, which helps measure tumor aggression, may also be instrumental in preventing chromosome errors linked to cancer development.
The findings, published on May 16, 2026, suggest that this protein could serve not only as a marker for tumor growth but also as a therapeutic target in cancer treatment.
As researchers continue to explore the implications of this study, it raises important questions about how existing cancer biomarkers can be repurposed to improve patient outcomes.